These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189 [TBL] [Abstract][Full Text] [Related]
4. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Andrew HG Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668 [TBL] [Abstract][Full Text] [Related]
5. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Abdul-Monim Z; Reynolds GP; Neill JC Behav Brain Res; 2006 May; 169(2):263-73. PubMed ID: 16500717 [TBL] [Abstract][Full Text] [Related]
6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. Plesnicar BK; Zalar B; Breskvar K; Dolzan V J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753 [TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
8. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437 [TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377 [TBL] [Abstract][Full Text] [Related]
10. Behavioural pharmacology of the new generation of antipsychotic agents. Moore NA Br J Psychiatry Suppl; 1999; (38):5-11. PubMed ID: 10884895 [TBL] [Abstract][Full Text] [Related]
11. Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio). Seibt KJ; Piato AL; da Luz Oliveira R; Capiotti KM; Vianna MR; Bonan CD Behav Brain Res; 2011 Oct; 224(1):135-9. PubMed ID: 21669233 [TBL] [Abstract][Full Text] [Related]
12. Predicting drug efficacy for cognitive deficits in schizophrenia. Hagan JJ; Jones DN Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277 [TBL] [Abstract][Full Text] [Related]
13. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. Gerlach J J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196 [TBL] [Abstract][Full Text] [Related]
14. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. Stip E J Psychiatry Neurosci; 2000 Mar; 25(2):137-53. PubMed ID: 10740987 [TBL] [Abstract][Full Text] [Related]
15. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. Casey DE; Bruhwyler J; Delarge J; Géczy J; Liégeois JF Psychopharmacology (Berl); 2001 Sep; 157(3):228-35. PubMed ID: 11605077 [TBL] [Abstract][Full Text] [Related]